Blue Fin Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Blue Fin Capital's XBI Position: Q3 2021 in Review
Blue Fin Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 1,499 shares — an estimated $202K sold.
Blue Fin Capital first reported a position in XBI in Q1 2021 and held it in 2 quarters. The position peaked at $202K in Q2 2021. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.
- Blue Fin Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
- Blue Fin Capital sold 1,499 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $202K.
- Blue Fin Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 2 quarters.
- Blue Fin Capital's State Street SPDR S&P Biotech ETF position peaked at $202K in Q2 2021.
- 635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.
Based on Blue Fin Capital's 13F filing for Q3 2021, filed 25 Oct 2021.